Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C

Hepatitis C, Chronic Clinical Trial

— SOF_GT2  

Official title:

Evaluation of Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Adults Chronically Infected With Genotype 2 Hepatitis C Virus: an Open-label, Multicenter Confirmatory Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03453346
• Other study ID #: BJKY-2016-003
• Secondary ID: CTR20160399
• Status: Completed
• Phase: N/A
• First received: February 27, 2018
• Last updated: March 5, 2018
• Start date: August 5, 2016
• Est. completion date: March 30, 2017

Study information

• Verified date: March 2018
• Source: Kawin Technology Share-holding Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aimed to evaluate the safety and efficacy of generic sofosbuvir, an investigational anti-hepatitis C virus (HCV) drug, combined with weight-adjusted ribavirin for treatment-naive Chinese adults chronically infected with genotype 2 HCV, the second most prevalent genotype in China. One hundred and thirty-two (132) subjects, including one hundred and twenty (120) non-cirrhotics and twelve (12) compensatory cirrhotics, were medicated with sofosbuvir 400 mg daily combined with weight-adjusted ribavirin 1000-1200 mg daily. The treatment course lasted 12 successive weeks and thereafter all the study participants entered into a 12-week treatment-free follow-up period.

Description:

It is estimated that China has a population of over 10 million infected with HCV and also a highly variable HCV genotype geographic distribution. Genotype 2 HCV is reported to be the second most common type (~25%) in Chinese population and associated with a high risk of acute liver disease exacerbation and other extrahepatic diseases. Sofosbuvir is a pan-genotypic HCV ribonucleic acid (RNA) polymerase inhibitor directing at HCV RNA replication. Genotype 2 chronic hepatitis C has a high treatment response to the combined regimen of peginterferon and weight-adjusted ribavirin. The all-oral combination regimen of sofosbuvir and ribavirin is expected to completely suppress genotype 2 HCV replication in subjects chronically infected with HCV and achieve a sustained virologic response, namely, HCV not detected or below a predefined limit in plasma, 12 or 24 weeks after cessation of treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 136
• Est. completion date: March 30, 2017
• Est. primary completion date: March 18, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• aged between 18 and 65 years (inclusive) and of either sex

• with a body mass index (BMI) between 18 and 30 kg/m^2

• chronically infected with genotype 2 HCV, and the diagnosis of chronic hepatitis C consistent with the Chinese Guideline for Prevention and Management of Hepatitis C

• HCV RNA equaling to or above 10^4 IU/mL and anti-HCV positivity

• naive to anti-HCV treatment, defined as being not previously treated with any interferon (including interferon alfa or beta or peginterferon), ribavirin, or other approved, investigational or any other not approved anti-HCV regimens of any source

• with or without cirrhosis, presence or absence of which must be documented as at lease one item of the following: 1) liver biopsy confirming presence (e.g., Metavir score = 4 or Ishak score >=5) or absence of cirrhosis within twelve (12) months before screening; 2) FibroScan showing cirrhosis (liver stiffness modulus [LSM]>=12.5 kPa) or no cirrhosis (LSM=<9.6 kPa); 3) a subject with a LSM of 9.6-12.5 kPa (exclusive) could only be enrolled when the liver biopsy confirmed or excluded presence of cirrhosis

• women of childbearing potential without a history of menopause and with a negative blood pregnancy test; subjects of childbearing potential (including male subjects and their female partners) had no childbearing plan from screening, initiation of treatment until six (6) months after the end of treatment and consented to use effective contraceptive measures

• voluntary participation in the study and being able to understand and sign the informed consent form

Exclusion Criteria:

• being infected with mixed-genotype HCV

• having previously used any investigational or experimental direct antiviral agents against HCV, including protease, nonstructural (NS) protein 5B polymerase or NS5A inhibitors, before screening

• having received any interferon-based anti-HCV regimens before screening

• having been exposed to any systemic potent immunomodulators , such as steroids or thymosin alfa (excluding use of nasal, inhalational, topical steroids and/or others) for more than two (2) weeks within six (6) months before screening, or anticipated to be exposed to these agents during the study period

• being coinfected with hepatitis B virus (HBV) or human immunodeficient virus (HIV)

• with evidence of decompensatory liver function, including but not limited to total serum bilirubin (TBIL) above twice (2) of the upper limit of normal (ULN), serum albumin (ALB) below 35 g/L, or prothrombin activity (PTA) below 60%; emergence of ascites, upper gastrointestinal bleeding and/or hepatic encephalopathy; with liver function reserve Child-Pugh class B or C

• with primary liver cancer confirmed or evidenced by serum alfa-fetoprotein above 100 ng/ml or liver imaging study showing suspected nodules

• with a previous history of liver disease of other causes, including alcoholic liver disease, nonalcoholic steatohepatitis, drug-induced hepatitis, autoimmune hepatitis (anti-nuclear antibody[ANA] titer above 1:100), Wilson disease or hemochromatosis

• with serum alaine aminotransferase (ALT) or asparate aminotransferase (AST) above ten (10) times of ULN

• with white blood cell (WBC) count below 3x10^9 per liter, neutrophil count below 1.5x10^9 per liter, platelet count below 50x10^9 per liter, or hemoglobin below the lower limit of the normal

• with serum creatinine clearance (CLcr) below 50 ml/min using the Cockcroft-Gault formula

• with uncontrolled diabetes mellitus (hemoglobin A1c[HbA1c] above 7.0%)

• with psychiatric or neurologic disorders, including previous or family history of psychiatric disorders (especially depression, depressive state, epilepsy or hysteria)

• with serious cardiovascular disorders, including uncontrolled hypertension (systolic blood pressure at or above 160 mmHg and/or diastolic blood pressure at or above 100 mmHg), heart insufficiency of New York Heart Association class III or above, history of myocardial infarction within six (6) months before screening, history of percutaneous transluminal coronary angioplasty within six (6) months before screening, unstable angina pectoris, or any uncontrolled arrhythmias

• with serious hematologic disorders (such as anemia, hemophilia and others)

• with serious kidney diseases (such as chronic kidney disease, kidney insufficiency and others)

• with serious gastrointestinal disorders (such as peptic ulcer, colitis and others)

• with serious respirator disorders (such as active pulmonary tuberculosis, lung infection, chronic obstructive pulmonary disease, pulmonary interstitial disease and others)

• with active or suspected malignant tumors or with a previous history of malignant tumors (excluding skin basal cell carcinoma or cervical carcinoma in situ) within five (5) years before screening

• with a history of major organ transplantation

• being known to be severely hypersensitive or allergic to any drugs, especially the testing medications and other constituents

• with a history of active alcohol or drug abuse

• being pregnant or lactating

• being unable to discontinue prohibited medications as defined by the protocol

• having participated in any other clinical studies within three (3) months before screening

• being unable or unwilling to provide informed consent or unable to follow the protocol requirements

• any other conditions of excluding a potential participant at the discretion of the investigators

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatitis C Virus Infection, Response to Therapy of
• Hepatitis C, Chronic
• Virus Diseases

Intervention

Drug:
• Sofosbuvir
Generic sofosbuvir tablet 400 mg
• Ribavirin
Ribavirin was provided in 100-mg tablets.

Locations

Country	Name	City	State
China	Capital Medical University Affiliated Beijing Ditan Hospital	Beijing	Beijing
China	Capital Medical University Affiliated Beijing You'an Hospital	Beijing	Beijing
China	Capital Medical University Affiliated Beijing Youyi Hospital	Beijing	Beijing
China	Chinese PLA 302 Hospital	Beijing	Beijing
China	Peking University People's Hospital	Beijing	Beijing
China	Jilin University First Hospital	Changchun	Jilin
China	Sichuan Provincial People's Hospital	Chengdu	Sichuan
China	Chinese PLA Third Military Medical University First Affiliated Hospital	Chongqing	Chongqing
China	Chongqing Medical University Affiliated Second Hospital	Chongqing	Chongqing
China	Nanjing Municipal Second Hospital	Nanjing	Jiangsu
China	Qingdao Municipal Hospital	Qingdao	Shandong
China	Shenyang Municipal Sixth People's Hospital	Shenyang	Liaoning
China	Hebei Medical University Affiliated Third Hospital	Shijiazhuang	Hebei
China	Chinese PLA Fourth Military Medical University Tangdu Hospital	Xi'an	Shaanxi
China	Xi'an Jiaotong University College of Medicine Affiliated First Hospital	Xi'an	Shaanxi
China	He'nan Provincial Hospital of Infectious Disease (Zhengzhou Municipal Sixth People's Hospital)	Zhengzhou	Henan
China	He'nan Provincial People's Hospital	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
Kawin Technology Share-holding Co., Ltd.	KawinGreen Biotech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Virologic breakthrough	Percentage of subjects with on-treatment re-detected plasma HCV RNA after HCV RNA below the lower limit of quantitation	2, 4, 8 and 12 weeks after initiation of treatment
Other	Virologic relapse	Percentage of subjects with off-treatment re-detected plasma HCV RNA after end-of-treatment HCV RNA below the lower limit of quantitation	4 and 12 weeks after end of treatment
Primary	Sustained virologic response at 12 weeks after end of treatment (SVR12)	Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)	12 weeks after end of treatment
Secondary	Sustained virologic response at 4 weeks after end of treatment (SVR4)	Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)	4 weeks after end of treatment
Secondary	Rapid virologic response at 1 week after initiation of treatment (RVR1)	Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)	1 week after initiation of treatment
Secondary	Rapid virologic response at 2 weeks after initiation of treatment (RVR2)	Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)	2 weeks after initiation of treatment
Secondary	Rapid virologic response at 4 weeks after initiation of treatment (RVR4)	Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)	4 weeks after initiation of treatment
Secondary	Rapid virologic response at 8 weeks after initiation of treatment (RVR8)	Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)	8 weeks after initiation of treatment
Secondary	Rapid virologic response at 12 weeks after initiation of treatment (RVR12)	Percentage of subjects with plasma HCV not detected or below the lower limit of quantitation (15 IU/mL)	12 weeks after initiation of treatment